Anti-CD-20 Monoclonal Antibody

I haven´t seen anything new on ofatumumab, ocrelizumab and veltuzumab. It seems that rituximab will stay the only anti-CD-20 monoclonal antibody in the market.


S. Menon and colleagues presented an abstract of a meta-analysis concerning B-cell depleting theapies, which still include studies of ofatumumab and ocrelizumab. The comparison between studies is made by effect size, which is a much better way to compare studies and we should call for publication of effect size of every study! Accordimng to the meta-analysis B-cell depleting therapies have “a large and highly reproducible effect on RA disease activity”.

[AB0572] META-ANALYSIS OF THE KEY RHEUMATOID ARTHRITIS (RA) DISEASE ACTIVITY ENDPOINTS IN PATIENTS TREATED WITH B-CELL DEPLETING THERAPIES
S. Menon, K. Barker, E. Peeva, I. Gourley, A. Heatherington. Research and Development, Pfizer Inc, Cambridge, United States
Conclusions: This meta-analysis indicates that in recent trials with B-cell depleting therapy, the therapies have a large and highly reproducible effect on RA disease activity which is not affected by prior receipt of anti-TNF therapy.